Gene Therapy Offers Lasting Remission for Transfusion-Dependent Beta-Thalassemia

A new gene therapy, betibeglogene autotemcel (beti-cel), is demonstrating sustained transfusion independence and long-term safety in individuals with transfusion-dependent beta-thalassemia (TDT), offering a potentially curative treatment option for this chronic blood disorder.

What is Beta-Thalassemia?

Beta-thalassemia is an inherited blood disorder that reduces the production of hemoglobin, the protein in red blood cells that carries oxygen. Individuals with TDT require regular blood transfusions to manage the condition, which can lead to iron overload and other complications.

How Does Beti-Cel Work?

Beti-cel is a stem cell-directed gene therapy. It involves collecting a patient’s own CD34+ hematopoietic stem cells and genetically modifying them using a lentiviral vector to insert a functioning copy of the HBB gene – the gene responsible for producing beta-globin, a key component of hemoglobin [2]. These modified cells are then infused back into the patient after they undergo myeloablative chemotherapy to make room for the new cells [3].

Long-Term Efficacy and Safety Data

Recent long-term follow-up data from a study published in Blood, involving 63 patients with TDT, show promising results. The median follow-up period was 5.9 years, with the longest follow-up reaching 10.1 years [1]. Key findings include:

• Transfusion Independence: 52 of 63 patients achieved transfusion independence.
• Durable Response: 68.2% of patients who received beti-cel in earlier phase studies (Phase 1/2) maintained transfusion independence, while 90.2% of those in later phase studies (Phase 3) did so.
• Improved Hemoglobin Levels: Median weighted average hemoglobin levels during transfusion independence were 10.2 g/dL (Phase 1/2) and 11.2 g/dL (Phase 3).
• Iron Chelation Discontinuation: 73% of patients who achieved transfusion independence were able to discontinue iron chelation therapy and showed no increase in liver iron concentration.
• Safety Profile: The therapy demonstrated a long-term safety profile consistent with myeloablative autologous transplantation. No instances of vector-derived replication-competent lentivirus, malignancy, or insertional oncogenesis were reported [1].

Researchers observed that improvements in manufacturing processes during Phase 3 studies led to increased transduction efficiency, resulting in higher levels of functional hemoglobin and improved transfusion independence rates compared to Phase 1/2 studies [1].

What Does This Imply for Patients?

These findings suggest that beti-cel can provide a durable, one-time treatment option for individuals with TDT, potentially eliminating the need for lifelong blood transfusions and improving their quality of life. The therapy restores iron balance and improves biomarkers related to red blood cell production [1].